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Abstract
Chromosomal region 17q12-q21 is associated with asthma and harbors regulatory polymor-
phisms that influence expression levels of all five protein-coding genes in the region:
IKAROS family zinc finger 3 (Aiolos) (IKZF3), zona pellucida binding protein 2 (ZPBP2),
ORMDL sphingolipid biosynthesis regulator 3 (ORMDL3), and gasdermins A and B
(GSDMA, GSDMB). Furthermore, DNA methylation in this region has been implicated as a
potential modifier of the genetic risk of asthma development. To further characterize the
effect of DNA methylation, we examined the impact of treatment with DNA methyltransfer-
ase inhibitor 5-aza-2’-deoxycytidine (5-aza-dC) that causes DNA demethylation, on expres-
sion and promoter methylation of the five 17q12-q21 genes in the human airway epithelium
cell line NuLi-1, embryonic kidney epithelium cell line 293T and human adenocarcinoma cell
line MCF-7. 5-aza-dC treatment led to upregulation of expression of GSDMA in all three cell
lines. ZPBP2 was upregulated in NuLi-1, but remained repressed in 293T and MCF-7 cells,
whereas ORMDL3 was upregulated in 293T and MCF-7 cells, but not NuLi-1. Upregulation
of ZPBP2 and GSDMA was accompanied by a decrease in promoter methylation. More-
over, 5-aza-dC treatment modified allelic expression of ZPBP2 and ORMDL3 suggesting
that different alleles may respond differently to treatment. We also identified a polymorphic
CTCF-binding site in intron 1 of ORMDL3 carrying a CG SNP rs4065275 and determined its
methylation level. The site’s methylation was unaffected by 5-aza-dC treatment in NuLi-1
cells. We conclude that modest changes (8–13%) in promoter methylation levels of ZPBP2
and GSDMA may cause substantial changes in RNA levels and that allelic expression of
ZPBP2 and ORMDL3 is mediated by DNA methylation.
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Introduction
Genome-wide association studies (GWAS) have identified thousands of loci associated with
human disease. In most cases, however, the genetic association alone cannot accurately predict
whether an individual carrier of the risk allele will develop the disease. Such an uncertain heri-
tability is explained by differences in environmental exposures or epigenetic variation between
individuals [1]. Therefore, it has been suggested that inter-individual variation in epigenetic
states, such as DNA methylation, may modify the risk of developing disease. Furthermore,
emerging data suggest that DNA methylation may act as a mediator of the effect of genotype
on gene expression or provide a mode of communication and adaptation between the genome
and environment (reviewed in [2]).
Chromosomal region 17q12-q21 harbours one of the best replicated GWAS regions associ-
ated with childhood asthma [3–6]. The 17q12-q21 common polymorphisms associated with
asthma delineate a genomic interval that encompasses five protein-coding genes: IKAROS
family zinc finger 3 (Aiolos) (IKZF3), zona pellucida binding protein 2 (ZPBP2), gasdermin B
(GSDMB), ORMDL sphingolipid biosynthesis regulator 3 (ORMDL3), and gasdermin A
(GSDMA). Expression of all of these genes depends on genotype in a number of different cell
types [3, 7, 8]. Two common haplotypes associated with expression levels and spanning about
160 kb were first delineated in studies of lymphoblastoid cell lines (LCLs) and termed HapA
and HapB [7, 9]. Haplotype HapA is associated with higher expression levels of ORMDL3 and
GSDMB in cells from peripheral blood, LCLs, mammary tissue, lungs and several other tissues;
ZPBP2 in testes and IKZF3 in the aorta [7]. Haplotype HapB (sum of all non-HapA haplotypes)
is associated with higher expression of ZPBP2 in LCLs and GSDMA in lungs and mammary
tissue [7–10]. The HapA haplotype harbors variants associated with childhood asthma [7]. It is
widely accepted that elevated expression of ORMDL3 confers higher risk for asthma [3, 11–
13]. However, IKZF3, GSDMA and GSDMB proteins are detected in human airway epithelial
cells, whereas ZPBP2 appears in the glandular epithelium of the bronchus, albeit at very low
levels[14]. Therefore, potential involvement of these genes in predisposition to airway disease
cannot be completely ruled out [7].
Both genetic and environmental factors contribute to asthma pathogenesis; therefore, a
number of studies have explored the relationship between genetic predisposition and environ-
mental exposures. Indeed, the genetic association between 17q12-q21 alleles and asthma was
stronger when exposure to tobacco smoke, farm animals and respiratory infections were taken
into account [15–19]. Multiple lines of evidence suggest that DNA methylation may act as
intermediary between genotype and phenotype or environment and phenotype [20–22]. In
line with such a role, DNA methylation levels in the 17q12-q21 genes also show association
with predisposition to asthma [1, 23]. Associations between promoter methylation and expres-
sion levels of ZPBP2 and GSDMB were found in LCLs [9]. Negative association between
ORMDL3 intron 1 methylation and ORMDL3 expression was also found in peripheral blood
cells [1].
The sum of current data supports the link between DNA methylation, genotype, gene
expression and asthma. However, to date, direct evidence for DNA methylation mediating or
modulating the genotype effect on 17q12-q21 gene expression is scarce. Furthermore, DNA
methylation differences between asthmatic and non-asthmatic subjects are rather modest
(within the range of 1 to 9%) [23, 24], which often raises the question of whether such small
changes in methylation levels have significant functional effects. It is also possible that differ-
ences in DNA methylation at certain regions may have no impact on gene expression.
The most parsimonious explanation for the role of DNA methylation in gene regulation is
that methylation of CGs located within transcription factor (TF) binding sites interferes with
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their binding to DNA leading to changes in transcription. Ample experimental evidence
shows that increased methylation in promoter or enhancer regions leads to gene silencing/
down-regulation [25–27]. The consequences of methylation of CGs located within the insula-
tor protein CCCTC binding factor (CTCF) binding sites (CBS) present a more complex para-
digm. CTCF plays a pivotal role in the 3D organization of chromatin and gene regulation
(reviewed in [28]). Methylation of CGs within the CBS prevents CTCF binding and causes dra-
matic changes in gene regulation due to remodeling of chromatin loops, with certain genes
being upregulated and other genes repressed [29–31]. Therefore, to understand the biological
processes affected by DNA methylation changes, the functions of the differentially methylated
CGs have to be taken into account.
To clarify the role of DNA methylation in the regulation of the 17q12-q21 asthma-associ-
ated region, we have examined the impact of DNA-methyltransferase 1 inhibitor 5-aza-2’-
deoxycytidine (5-aza-dC) on DNA methylation of regulatory elements and gene expression in
3 human epithelium cell lines: airway epithelium cell line NuLi-1, the embryonic kidney epi-
thelium cell line 293T and the epithelial metastatic breast adenocarcinoma cell line MCF-7.
We found that these different cell lines respond differently to 5-aza-dC treatment. We also
observed that modest changes in DNA methylation caused a several-fold increase in the
expression of ZPBP2 and GSDMA, the same genes that show methylation differences between
asthmatic and non-asthmatic subjects in blood cells [23], and that the allelic expression bias of
ZPBP2 and ORMDL3 depended on methylation in NuLi-1 cells.
Materials and methods
Cell lines and cell culture
List of cell lines used in this study is provided in S1 Table. The human airway epithelial cell
line, NuLi-1, was derived from a normal lung of a 36-year-old male patient by dual retrovi-
ral infection to prevent cells undergoing growth arrest in cell culture [32]. The CuFi-1
airway epithelial cell line was derived from the lung of a 14-year-old female patient with
cystic fibrosis by the same method and is homozygous for the CFTRΔF508 mutation [32].
These cells were purchased from the ATCC. N3 (normal bronchial epithelial cells), CF2
(homozygous for the CFTRΔF508 mutation) and CF7 (CFTRG551D mutation) cells were
kindly provided by Dr Scott Randell (Cystic Fibrosis/Pulmonary Research and Treatment
Center, The University of North Carolina, Chapel Hill, North Carolina) [32]. All of these
cells were cultured on collagen I and maintained at 37˚C, 5% CO2, 100% humidity, in Bron-
chial Epithelial Growth Medium (Lonza, Walkersville, MD) supplemented with growth
factors (SingleQuots (Lonza), except gentamicin), 50 U/ml penicillin G and 50 μg/ml
streptomycin.
The human embryonic kidney cell line 293T was cultured in Dulbecco’s modified Eagle’s
medium (DMEM, 319-006-CL; Wisent BioProducts, QC, Canada) at 37˚C, 5% CO2, and 100%
humidity. Culture medium was supplemented with heat-inactivated (10% v/v) fetal bovine
serum (FBS, 080–450; Wisent Bioproducts, QC, Canada), 50 U/ml penicillin G, 50 μg/ml
streptomycin. These cells were purchased from ATCC.
The human adenocarcinoma MCF-7 cells were grown in DMEM medium (Gibco, Life
Technologies) supplemented with 10% FBS, 25mM HEPES, 50 U/ml penicillin and 1.6 mg/ml
gentamycin. Cells were incubated at 37˚C, 5% CO2, and 100% humidity. These cells were pur-
chased from ATCC.
5-aza-2’-deoxycytidine (5-aza-dC) (Sigma-Aldrich, USA) was dissolved in DMSO at 50
mg/ml. NuLi-1 cells (passages 17–21) were plated in 60 × 15 mm Petri dishes (1.5 x 105 cells
per plate) and treated with 0.5 μM 5-aza-dC in 0.5% DMSO or 0.5% DMSO alone for 24h.
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After 24h, the medium was changed and cells were grown for another 7 days. Cells were har-
vested for RNA and DNA extraction. Effect of 5-aza-dC on expression was evaluated in 4, and
the effect on DNA methylation—in 3 independent replicate experiments. A similar treatment
was done for MCF-7 cells in 3 replicate experiments. The most efficient treatment for 293T
cells was at 50 μM 5-aza-dC concentration. After initial 5-aza-dC treatment, 293T cells were
cultured for 3 days. The 293T experiment was done in triplicate. Imprinted gene H19 whose
expression increases with promoter demethylation was used as control for treatment
efficiency.
Genotyping
Epithelial cell line 17q12-q21 genotypes were established using PCR assays targeting SNPs in
the ZPBP2 and ORMDL3 genic regions followed by Sanger sequencing. Sequencing was done
by the McGill University and Genome Quebec Innovation Centre sequencing service. PCR
primers are listed in S2 Table.
Expression analysis and FAIRE assays
RNA was extracted using Trizol reagent (Life Technologies) and purified using RNeasy MinE-
lute Cleanup Kit (Qiagen). Quantitative real-time RT-PCR (qPCR) was performed using
Power SYBRR Green PCR Master mix (Applied Biosystems, San Diego, CA, USA) in the Eco™
Real-Time PCR System (Illumina, San Diego, CA, USA). Data were normalized by 18S RNA
levels and analyzed using the 2(-delta-delta C(T)) method [33]. Statistical significance of
expression differences between 5-aza-dC treated cells and controls was evaluated using the
Student’s t-test.
Allelic expression of genes from the human chromosomal region 17q12-q21 was analyzed
using RT-PCR followed by Sanger sequencing. For each of the analyzed genes, primers target-
ing exonic SNPs were selected. Primers and targeted SNPs are listed in S2 Table. Sequencing
was done by the McGill University and Genome Quebec Innovation Centre sequencing ser-
vice. Allelic ratios were determined using the PeakPicker software [34].
DNA from previously described FAIRE assays [7, 9] was used to determine the effect of
SNP rs4065275 on nucleosome occupancy.
Sodium bisulfite methylation assays
Sodium bisulfite sequencing DNA methylation assays for ZPBP2, ORMDL3, and GSDMA pro-
moters were conducted as previously described [9, 35]. On average, 24 clones per sample were
sequenced. Clone sequences were analyzed and the average percent of methylation was calcu-
lated for the region (number of methylated CG vs. number of assayed CGs) and for each indi-
vidual CG position.
Pyrosequencing assays for ZPBP2 and GSDMA were conducted as previously described [23,
35]. The pyrosequencing assay for the CTCF sites C9a and C9b located within intron 1 of
ORMDL3 was designed with PyroMark Assay Design 2.0 software. Bisulfite conversion was
done using the EpiTect bisulfite kit (Qiagen). The pyrosequencing assay was performed with
PyroMark Q24 Advanced CpG Reagents (Qiagen) in the PyroMark Advanced Q24 system.
Percentage of DNA methylation per CG site was analyzed with PyroMark Q24 Advanced 3.0.0
software. Statistical significance of the change in methylation was evaluated using the Student’s
t-test.
DNA methylation and gene expression in the 17q12-q21 region
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Results
DNA methyltransferase 1 inhibitor 5-aza-2’-deoxycytidine treatment
alters gene expression in the 17q12-q21 region
To determine the impact of 5-aza-dC, we examined expression levels and allelic expression of
five 17q12-q21 genes in NuLi-1, 293T and MCF-7 cells (S1 Table). In all 3 cell lines, treatment
with 5-aza-dC led to inhibition of cell proliferation and upregulation of H19 expression (Fig
1A and 1B). Expression levels of ORMDL3 were not affected in NuLi-1, but increased 1.2 and
1.4-fold in MCF-7 and 293T cells, respectively (Fig 1B). GSDMA was upregulated in all three
cell lines. GSDMB was upregulated in NuLi-1 and 293T cells, with no significant change in
MCF-7 cells (Fig 1B). ZPBP2 was expressed only in the NuLi-1 cell line before treatment and
was upregulated almost 20-fold, but remained silent in 293T and MCF-7 cells. IKZF3 was
expressed in NuLi-1 and 293T cells; it was upregulated in 293T but not NuLi-1 cells post
5-aza-dC treatment.
Allelic expression analysis was possible only in NuLi-1 cells that are heterozygous for the
IKZF3-GSDMA genomic interval; 293T and MCF-7 cells are homozygous and therefore not
informative. In control NuLi-1 cells, allelic bias was detected in the expression of IKZF3 and
ZPBP2 in favor of the HapB alleles, ORMDL3 and GSDMA in favor of the HapA alleles;
GSDMB was expressed equally from both alleles. 5-aza-dC treatment caused a switch in the
allelic bias of ORMDL3 gene expression from the HapA to the HapB allele. It also reactivated
the silent ZPBP2 HapA allele making the ZPBP2 allelic bias in favor of the HapB allele less
extreme (Fig 1C).
5-aza-dC treatment changes DNA methylation at ZPBP2 and GSDMA
promoters
The most pronounced effect of 5-aza-dC on expression levels was seen for ZPBP2 in NuLi-1
and for GSDMA in all three cells lines. To determine if up-regulation of ZPBP2 and GSDMA
expression was due to promoter demethylation, we conducted DNA methylation assays in
NuLi-1 and 293T cells. After treatment with 5-aza-dC, the average methylation level of the
ZPBP2 promoter was reduced to 5% from 16% in NuLi-1 cells as determined using the sodium
bisulfite sequencing methylation assay (Fig 1E). Loss of methylation was confirmed using the
pyrosequencing methylation assay (S3 Table). In 293T cells, the ZPBP2 promoter was hyper-
methylated and treatment had very little effect on its methylation level (64.3% vs 62.3%, con-
trol vs treatment). Average methylation of the GSDMA promoter was reduced to 25% from
57% in NuLi-1 cells and to 61% from 74% in 293T cells. The methylation of GSDMA-CG1,
which shows lower methylation in asthmatic females [23], was reduced to 0% from 9% in
NuLi-1 and to 23% from 31% in 293T cells. DNA from treated MCF-7 cells was not available
for analysis. Thus, for ZPBP2 and GSDMA promoters, reducing methylation by as little as 8%
or 13% was accompanied by a marked increase in expression (Figs 1 and 2, and S3 Table).
To determine if changes in ZPBP2 allelic bias in NuLi-1 cells was also the result of demeth-
ylation, we analyzed allelic methylation levels (Fig 1E). The HapB allele of the ZPBP2 promoter
was less methylated than the HapA allele in both controls and 5-aza-dC treated cells (10% vs
20% methylation in controls, and 2% vs 8% in treated cells, respectively) (Fig 1E). It is worth
noting that CG31, one of the 5 CGs (31, 40, 41, 48, 51) which showed the largest differences
between alleles as well as the biggest loss of methylation after 5-aza-dC treatment, resides near
the transcriptional start site of ZPBP2. The decrease in CG31 methylation on the HapA allele
to 36% from 88% may explain upregulation of ZPBP2 expression from this allele after 5-aza-
dC treatment.
DNA methylation and gene expression in the 17q12-q21 region
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Fig 1. 5-aza-dC treatment enhances gene expression. (A) 5-aza-dC treated NuLi-1 cells show reduced proliferation and apoptosis
four days after treatment. Arrowheads point to dying/dead cells. (B) Changes in expression levels of 17q12-q21 genes after 5-aza-dC
treatment. The y-axis shows fold change in 5-aza-dC treated cells compared to controls. Error bars show standard deviation. Asterisks
indicate statistically significant change in expression in 5-aza-dC treated cells compared to controls (* p < 0.05). (C) Allelic expression in
17q12-q21 genes after 5-aza-dC treatment. Arrows show positions of transcribed SNPs in those genes where allelic expression changed
post 5-aza-dC treatment. In ZPBP2, 5-aza-dC treatment causes reactivation of the HapA allele. In ORMDL3 it causes a switch in allelic
preference. (D) Positions of 51 CGs in the ZPBP2 promoter region that were assayed using the sodium bisulfite sequencing assay are
DNA methylation and gene expression in the 17q12-q21 region
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To determine whether changes in the allelic expression bias of ORMDL3 resulted from pro-
moter demethylation, its methylation was also assayed. The ORMDL3 promoter was hypo-
methylated in NuLi-1 5-aza-dC treated and control cells (S1 Fig). Therefore, we hypothesized
that changes in allelic expression of ORMDL3 resulted from changes in DNA methylation at
another regulatory region, such as CTCF-binding site.
shown in the context of the UCSC browser. The red box indicates the position of the 11 CGs assayed using the pyrosequencing
methylation assay. (E) DNA methylation profiles of the ZPBP2 promoter region in control (DMSO) and 5-aza-dC treated cells. Filled
circles represent methylated CGs, open circles represent unmethylated CGs. Each row represents a clone. Data are divided by
haplotype; allelic percent methylation is shown below the diagram. Type of treatment and average methylation levels are shown on top.
Arrow points to CG31 (CG6 in pyrosequencing assays) that has one of the most pronounced allelic differences in methylation.
doi:10.1371/journal.pone.0172707.g001
Fig 2. DNA methylation patterns of the GSDMA promoter in NuLi-1 cells. (A) Positions of the
interrogated CGs with respect to the GSDMA promoter region are shown in the context of the UCSC browser.
(B) GSDMA promoter methylation changes after 5-aza-dC treatment. Filled circles represent methylated
CGs, open circles represent unmethylated CGs. Each row represents a clone, the number on the right
indicates the number of clones with a particular methylation pattern. Data are divided by allele; allelic percent
methylation is shown below the diagram. Type of treatment and average DNA methylation are shown on top;
hA -haplotype A; hB–haplotype B.
doi:10.1371/journal.pone.0172707.g002
DNA methylation and gene expression in the 17q12-q21 region
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Polymorphic and DNA-methylation sensitive CTCF binding sites in the
IKZF3-GSDMA region
The IKZF3-GSDMA region harbors 12 CTCF-enriched regions identified by ChIP-seq [36] (S2
Fig). We used the CTCF motif prediction tool (http://insulatordb.uthsc.edu [37]) to identify
the CTCF binding motifs and determine if there were common SNPs that occurred in the
CBS and that could change CTCF binding in these 12 CTCF enriched regions and two addi-
tional regions, C5 and C6, located within the ZPBP2 promoter region (S4 Table). Two of the
predicted CBS contained SNPs within the CTCF-binding motif: rs4065275 in intron 1 of
ORMDL3 (CBS C9b) and the previously reported rs12936231 in intron 5 of ZPBP2 (CBS C7a)
[7] (Fig 3 and S4 Table). To validate our predictions, we examined the CTCF ChIP-seq Uni-
form Peaks from ENCODE/Analysis ENCODE (March 2012 Freeze) [36] for genotype-depen-
dent CTCF enrichment. Genotype data were available for HapMap LCLs and obtained from
the HapMap database [38]. Indeed, three cell lines GM12891, GM12878 and GM19238 that
were homozygous or heterozygous for the rs4065275-G allele had higher CTCF-enrichment
compared to rs4065275-A homozygous cell lines GM12892, GM19239, GM19240 and MCF-7
in the C9 region (Fig 3A).
CTCF binding is usually associated with nucleosome repositioning and lower nucleosome
occupancy that may be detected by formaldehyde-assisted identification of regulatory ele-
ments (FAIRE) assays [39]. Therefore, allelic bias in FAIRE enrichment at the rs4065275
region in ORMDL3 was tested using heterozygous LCLs. The CBS C7b region in ZPBP2 was
used as control (data not shown). The CBS C9b region showed allelic differences in FAIRE
enrichment in three of the 4 assayed LCLs with higher enrichment of the rs4065275-G (C on
the reverse strand) allele corresponding to the HapA haplotype (Fig 3B). Hence, our data con-
firm that rs4065275 modifies nucleosome occupancy in an allele-specific fashion.
Within the C9 CTCF-enriched region of ORMDL3, the predicted non-polymorphic CBS
C9a and the rs4065275-G allele of the polymorphic CBS C9b contain CG sites. To determine if
methylation of these two sites varied between epithelial cell lines, pyrosequencing methylation
assays were conducted in 293T, NuLi-1 and MCF-7 cells as well as CF2, CF7, N3 and CuFi-1
cell lines derived from human airway epithelium. Methylation levels ranged between 9% and
49% in C9a and between 6% and 58% in C9b (Fig 3C). This variability is higher than observed
in human peripheral blood cells [1].
To determine if the allelic effect of 5-aza-dC treatment on ORMDL3 allelic expression was
due to change in C9b-CG methylation, we analyzed methylation of CBS C9a and C9b in the
heterozygous NuLi-1 cells. There was no significant change in the C9b CG methylation level
(S3 Table). The C9a CG methylation was reduced to 16% from 21% upon 5-aza-dC treatment,
but the change was also not statistically significant (S3 Table). Since the polymorphic CBS C9b
was hypomethylated and its methylation level did not show significant change, it is unlikely
that this CG is responsible for the allelic bias in ORMDL3 transcription.
Discussion
Our previous work demonstrated that lower methylation levels of certain CGs in the ZPBP2
and GSDMA promoters in peripheral blood cells are associated with asthma in females [23].
Here, we demonstrate that a modest decrease in average promoter methylation levels of these
two genes causes dramatic upregulation of their transcription (4 to 20-fold increase). There-
fore, differences in promoter methylation levels that were found between asthmatic and non-
asthmatic females [23] are likely to be functionally relevant.
Interestingly, in our experiments, none of the genes that were silent in control cells became
transcriptionally active after 5-aza-dC treatment. This may be due to a limited efficiency of
DNA methylation and gene expression in the 17q12-q21 region
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5-aza dC in heterochromatic regions. Moreover, in 293T and MCF-7 cells, we observed very
modest, if any, up-regulation of GSDMB, whereas in NuLi-1 cells GSDMB was upregulated
4-fold. Perhaps the lower methylation levels and open chromatin that is permissive for tran-
scription in the ZPBP2 region in NuLi-1 cells facilitates the effect of 5-aza-dC on the neighbor-
ing GSDMB.
To determine if DNA methylation was a mediator of the effect of genotype on gene expres-
sion levels or genotype effects were independent from methylation levels, we examined allelic
Fig 3. Polymorphic CTCF binding site rs4065275 (C9b) shows genotype dependent CTCF-binding, FAIRE enrichment
and variable methylation levels. (A) Effect of genotype on CTCF-enrichment at the rs4065275 SNP region. Cell lines that carry
the rs4065275-G allele show CTCF enrichment, whereas cell lines that carry the rs4065275-A allele do not. (B) Allelic bias in
FAIRE enrichment in LCLs. In 3 out of 4 cell lines the rs4065275-G (C in the diagram) is enriched in the nucleosome-free fraction.
(C) Methylation levels of the two putative CBS within the C9 CTCF-enriched region, rs4065275 CG (C9b) and the adjacent non-
polymorphic CG (C9a), in human epithelial cells were determined using a pyrosequencing methylation assay. Name of cell line
and rs4065275 genotype are shown below the x-axis.
doi:10.1371/journal.pone.0172707.g003
DNA methylation and gene expression in the 17q12-q21 region
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expression of 17q12-q21 genes before and after 5-aza-dC treatment. Two genes showed
changes in allelic expression ratios, ZPBP2 and ORMDL3. The other two genes with allelic bias
in expression, IKZF3 and GSDMA, maintained their allelic bias independent from an increase
in overall expression levels. Allelic expression bias is largely attributed to SNPs altering tran-
scription factor binding sites and is associated with a specific chromatin signature [7, 40–42].
DNA methylation has a pivotal role in controlling monoallelic expression of imprinted genes.
Our data suggest that, for certain non-imprinted genes, DNA methylation is responsible for
allelic expression, which is consistent with previous reports of complex relationships between
DNA methylation and expression [43].
Changes in DNA methylation of different regulatory elements, such as promoters,
enhancers and insulators, impact gene expression. The ORMDL3 promoter is hypomethy-
lated in all three tested cell lines and, hence, cannot be demethylated. However, ORMDL3
was upregulated in 293T and MCF-7 cells, whereas, in NuLi-1 cells, expression levels
remained unchanged but its allelic bias in expression was reversed towards the HapB allele.
This suggested that another regulatory region was involved which led us to test the hypothe-
sis that allelic expression of ORMDL3 depended on methylation of a polymorphic CTCF-
binding site.
Here we report that the common CG SNP rs4065275 located within a CBS modifies nucleo-
some positioning in such a way that the rs4065275-G allele is enriched in nucleosome-free
DNA. Unlike the rs12936231 polymorphic CBS, the rs4065275 polymorphic site does not dis-
rupt the CTCF-binding motif, but changes CTCF-enrichment in vivo. It is worth noting that
rs4065275 has been implicated in predisposition to asthma, regulation of ORMDL3 expression
levels and TF binding in peripheral blood mononuclear cells and in vitro assays [44]. One
would therefore expect that the unmethylated rs4065275 CG site would enhance CTCF-bind-
ing, whereas the hypermethylated would reduce it. Our data suggest that methylation of the
rs4065275-associated CG site is highly variable in epithelial cell lines, but not sensitive to
5-aza-dC treatment in the NuLi-1 cells.
In summary, we find that the response to 5-aza-dC, a chemical that is the basis for anti-can-
cer drug decitabine, varies among different cell lines. These data suggest that the same envi-
ronmental trigger may elicit different phenotypic responses from different individuals at the
levels of DNA methylation and gene expression. It is also worth noting that the NuLi-1, 293T
and MCF-7 cell lines assayed in our study are derived from different tissue sources and have
different modal chromosome numbers. Furthermore, NuLi-1 cells are derived from a male
donor, whereas 293T and MCF-7 are from female donors. Therefore, karyotype, sex, and cell
type may be critical factors when it comes to response to demethylation. Further studies are
necessary to determine to what extent local genotype, sex and cell type account for such a
variance.
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dent 5-aza-dC treatment experiments.
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S4 Table. Predicted CTCF-binding sites (CBS) within the CTCF-enriched regions of chro-
mosomal region 17q12-q21 using the CTCF motif prediction tool (http://insulatordb.
uthsc.edu (37)).
(PDF)
S1 Fig. DNA methylation of the ORMDL3 promoter in NuLi-1 cells. Filled circles represent
methylated CGs, open circles represent unmethylated CGs, gray circles represent sequencing
errors. Each row represents a clone, the number on the right indicates the number of clones
with a particular methylation pattern. Percent methylation is shown below the diagram. Type
of treatment is shown at the right. The position of the ORMDL3 exon 1 is shown on top.
(TIF)
S2 Fig. Map of putative CTCF-binding sites in the 17q12-q21 region. Top panel. Data from
the Transcription Factor ChIP-seq Uniform Peaks from ENCODE/Analysis are shown in the
context of the UCSC browser (https://genome.ucsc.edu). The putative CTCF-binding regions
IDs are shown at the bottom. Polymorphic CTCF binding sites shown in red. Bottom panel:
the ZPBP2 promoter region and location of putative CTCF binding sites. ID numbers corre-
spond to those in S4 Table.
(TIF)
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